Testing a Decision Tool to Adjust Levothyroxine Dose Early
Tests a decision tool that guides early levothyroxine dose changes in adults after thyroid removal.
Plain-language title generated from the registry record
Registry title: Patient-centered Dosage of Levothyroxine
Key facts
- Where
- Bergen, Oslo, and Tromsø, NorwaySee the 3 sites
Where in Norway
- Haukeland University HospitalBergen, NorwayTaking people
- Oslo University HospitalOslo, NorwayTaking people
- University Hospital of North NorwayTromsø, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital of North Norway
- Trial code
- NCT06455371
- Record updated
- 10 September 2025
- Original description
Levothyroxine is the most used thyroid hormone replacement when the thyroid gland is failing. Because dosage adjustment normally takes several months, the investigators have developed a decision support tool (DST) that predicts optimal dosage based on repeated blood samples the first 2 weeks after initiation of therapy. In this randomized study the investigators will include patients that start levothyroxine therapy after total thyroidectomy. The use of DST to advice the physician about an early dosage adjustment will be compared with common clinical practice, that is dosage adjustment every 2 months. The effect of DST use will be assessed by studying the possible relationship between fast optimal dose adjustment, patient reported outcome measures, and ability to work.Read full original descriptionShow less
Patient-centered Decision Support Tool for Levothyroxine Dosage
Levothyroxine is the most used thyroid hormone replacement when the thyroid gland is failing. Because dosage adjustment normally takes several months, the investigators have developed a decision support tool (DST) that predicts optimal dosage based on repeated blood samples the first 2 weeks after initiation of therapy. In this randomized study the investigators will include patients that start levothyroxine therapy after total thyroidectomy. The use of DST to advice the physician about an early dosage adjustment will be compared with common clinical practice, that is dosage adjustment every 2 months. The effect of DST use will be assessed by studying the possible relationship between fast optimal dose adjustment, patient reported outcome measures, and ability to work.
Inclusion: Total or completion thyroidectomy for differentiated thyroid cancer og benign thyroid nodules at Norwegian hospitals.
Exclusion: Anaplastic thyroid cancer, thyroid cancer with distant metastasis, graves disease, toxic nodules, pregnancy.